An interventional study of Sokru device in Diabetes Mellitus, sponsored by DCB Research AG. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-06-29.
Sponsored by DCB Research AG · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Diabetes Mellitus with a site in Switzerland — 9 open to participants now, 11 under way, none of them phase 3. Diabetes Mellitus · Switzerland.
Among the 87 studies in Diabetes Mellitus with a site in Switzerland, this one is the 57th largest by enrollment of the 63 interventional ones that give a count, is one of 7 that started in 2023, is one of 31 with no phase, and was the 78th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →9 of the 87 studies in Diabetes Mellitus with a site in Switzerland are open now. Recruiting first, the newest first:
University Hospital, Geneva · Sites in Switzerland
Ages 18+
Medtronic Vascular · Sites in Switzerland, United States, Australia and 3 more countries
Ages 18–80
Sleepiz AG · Sites in Switzerland
Ages 18+ · Healthy volunteers
University of Bern · Sites in Switzerland
Ages 18+ · Healthy volunteers
University Hospital, Basel, Switzerland · Sites in Switzerland, Lesotho
Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 19 · Phase 4 4
First in 1994; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 141 across the 63 interventional studies, 600 across the 24 observational. Of the 67 that completed or were terminated, 11 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 87 have an industry lead sponsor. The 10 most frequent:
DCB Research AG is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
DCB Research AG has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
3 of the studies in Diabetes Mellitus with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06715514Lia BallyMenopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis | 2026-12-17 |
| NCT07506356University Hospital, GenevaInvestigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors | 2026-12-31 |
| NCT07036471University of Geneva, SwitzerlandSupporting Patients Starting New Medicines: Evaluating the myCare Start Service in Switzerland | 2027-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 87 studies in Diabetes Mellitus with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary aim of this clinical study is to find signal characteristics of VOCs detected by Sokru device during fasting, insulin injection and after glucose intake and to find the association with blood glucose variation in variant states of glycemia and hypoglycemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the study arm will undergo the study procedure which are different induced glycaemic states.
Device: Sokru device
Different induced glycaemic states in people living with diabetes (PwD).
Characteristics of volatile organic compound (VOC) signals measured by the Sokru device
The primary outcome are changes in VOC signals measured by the Sokru at low glucose levels (below 3.0 -3.9 mmol/L) or during the time when the blood glucose level is decreasing (from 10 and 3.9 mmol/L).
Time frame: During the study procedure (approximately 5 hours)
Volatile Organic Compound Signals
VOC signals measured by the Sokru device at different blood glucose levels
Time frame: During the study procedure (approximately 5 hours)
Blood glucose concentration
Blood glucose levels are measured with the continuous glucose measurement system and in the venous blood at the time of the appearance of VOC signal peaks or drops
Time frame: During the study procedure (approximately 5 hours)
Time of onset of subjective symptoms of hypoglycemia
Self-reported onset of subjective symptoms of hypoglycemia
Time frame: During the study procedure (approximately 5 hours)
Heart rate
Heart rate is measured with a Mindray device
Time frame: During the study procedure (approximately 5 hours)
Oxygen saturation
Oxygen saturation is measured with a Mindray device
Time frame: During the study procedure (approximately 5 hours)
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2023 to primary completion in Jun 2023, 2 months.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 2 months is below that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
DCB Research AG